Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 16,380 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Central Nervous System Disease Clear all
Completed Phase 2 Interventional Results available

Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

NCT05605301
View directory record Official record
Conditions
Epilepsy; Seizure
Interventions
Oral 2-Deoxy-D-Glucose (2DG)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Recruiting Phase 2 Interventional

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study

NCT05104983
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Darcy Krueger
Other
Eligibility
1 Day to 6 Months
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures

NCT05288283
View directory record Official record
Conditions
Seizures Associated With EMAS
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 2 Interventional

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

NCT00361166
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-103
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2007 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated Phase 3 Interventional Results available

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

NCT00991029
View directory record Official record
Conditions
Ischemic Attack, Transient
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4,881 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
147
States / cities
Chandler, Arizona • Tucson, Arizona • Carmichael, California + 95 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated No phase listed Observational

An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US

NCT05097131
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
22
States / cities
Chula Vista, California • Valencia, California • Boca Raton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX

NCT00314145
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
ChimeriVax™-JE, JE-VAX®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
5
States / cities
Chicago, Illinois • Shawnee Mission, Kansas • Missoula, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 17, 2026, 12:38 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)

NCT05823766
View directory record Official record
Conditions
Traumatic Brain Injury, Post-traumatic Epilepsy
Interventions
In-Person Outcome Assessment, 3T Magnetic Resonance Imaging (MRI), Clinical Visit, Blood Draw, EEG, Telephone Outcome Assessment
Behavioral · Procedure
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
9
States / cities
San Francisco, California • Charlestown, Massachusetts • Cincinnati, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

Tanezumab in Osteoarthritis of the Knee

NCT00733902
View directory record Official record
Conditions
Arthritis, Osteoarthritis
Interventions
tanezumab, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
697 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
82
States / cities
Phoenix, Arizona • Danbury, Connecticut • Stamford, Connecticut + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 17, 2026, 12:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exercise Habits: A Survey of Individuals With Parkinson's Disease Living in the Community

NCT05011175
View directory record Official record
Conditions
Parkinson Disease
Interventions
Survey
Other
Lead sponsor
Jordana Lockwich
Other
Eligibility
40 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 17, 2026, 12:38 PM EDT
Enrolling by invitation No phase listed Observational

SLC13A5 Deficiency Natural History Study - United States Only

NCT06144957
View directory record Official record
Conditions
Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (Non-ROGDI), Citrate Transporter Disorder, DEE25
Interventions
Not listed
Lead sponsor
TESS Research Foundation
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Palo Alto, California • Providence, Rhode Island • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 17, 2026, 12:38 PM EDT
Recruiting Phase 2 Interventional

Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture

NCT05116930
View directory record Official record
Conditions
Post-Dural Puncture Headache
Interventions
Neostigmine, Glycopyrrolate
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated Not applicable Interventional

MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

NCT00504205
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study, positron emission tomography
Drug · Other · Procedure
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 17, 2026, 12:38 PM EDT
Recruiting Not applicable Interventional

Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI)

NCT07385105
View directory record Official record
Conditions
Sleep Architecture, Mild Traumatic Brain Injury, Sleep, Sleep and Circadian Problems
Interventions
Cognitive behavioral Therapy for insomnia (CBT-I)
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.

NCT02064166
View directory record Official record
Conditions
Parkinson Disease, Multiple System Atrophy
Interventions
Intranasal Insulin
Drug
Lead sponsor
Peter Novak
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2018 · Synced Oct 17, 2026, 12:38 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 2 Interventional

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00004200
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
prinomastat, temozolomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392
View directory record Official record
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Transcranial Direct Current Stimulation (tDCS)-Enhanced Stroke Recovery

NCT01007136
View directory record Official record
Conditions
Ischemic Stroke
Interventions
tDCS, Sham tDCS
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 17, 2026, 12:38 PM EDT
Terminated Phase 4 Interventional Results available

Burden of Obstructive Sleep Apnea in Stroke (BOSAST)

NCT00952211
View directory record Official record
Conditions
Stroke, Obstructive Sleep Apnea
Interventions
CPAP, CPAP at sub-therapeutic pressure
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
45 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Oct 17, 2026, 12:38 PM EDT
Enrolling by invitation No phase listed Observational

Florida Neonatal Neurologic Network

NCT02260271
View directory record Official record
Conditions
Hypoxic-Ischemic Encephalopathy
Interventions
Database Entry/Biospecimen Collection
Other
Lead sponsor
University of Florida
Other
Eligibility
1 Day to 3 Weeks
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2045
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Not applicable Interventional

A Study Evaluate Aqueduct's Smart External Drain

NCT03113799
View directory record Official record
Conditions
Hydrocephalus, Hydrocephalus in Children, Tumor, Brain
Interventions
Smart External Drain - SED
Device
Lead sponsor
Aqueduct Critical Care
Industry
Eligibility
5 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 17, 2026, 12:38 PM EDT
Completed Not applicable Interventional

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma

NCT04402632
View directory record Official record
Conditions
Subdural Hematoma
Interventions
Surgical Management, Onyx™ Liquid Embolic System (LES) Embolization, Observation Only
Procedure · Device · Other
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 90 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 44 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 17, 2026, 12:38 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

CBD Delivery with the A-Synaptic GT4 Transdermal Delivery System in with Dravet Syndrome And/or Lennox-Gastaut Syndrome

NCT06738732
View directory record Official record
Conditions
Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS)
Interventions
CBD: GT4 Transdermal Delivery System
Drug
Lead sponsor
Alexander Rotenberg
Other
Eligibility
2 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 17, 2026, 12:38 PM EDT